Brain ferric iron content following ICH and blockade or stimulation of the EP1 receptor. Antagonist (SC-51089, 10 µg/kg), agonist (17-pt-PGE2, 0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post-ICH, and at 12-h intervals thereafter. Seventy-two hours after ICH, brains were harvested and sections processed for Perl’s staining and ferric iron content determination. a Representative high magnification photomicrographs showing ferric iron (blue) accumulation in the perihematomal regions of control (left panel), SC-51089- (middle panel), and 17-pt-PGE2- (right panel) treated mice. Square selections in the insets denote magnified regions. Scale bars on the magnified images and insets are 100 µm and 1 mm, respectively. b Quantification of brain ferric iron content in the ipsilateral hemisphere showed that SC-51089-treated mice had significantly more ferric iron accumulation, whereas no significant differences were seen for the 17-pt-PGE2-treated mice. No ferric iron deposition was seen in the contralateral hemisphere for any of the mice in the study. *p < 0.05 when compared to the control group, n = 8–10 per group.